logo-loader
N4 Pharma PLC

N4 Pharma's Nuvec platform 'on a clear path' towards clinical trials

N4 Pharma PLC (LON:N4P) CEO Nigel Theobald speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019.

He says it's been an incredibly active period for them where, among a number of developments, they've confirmed that Nuvec® works for both DNA and mRNA delivery.

Quick facts: N4 Pharma PLC

Price: 3.575 GBX

Market: AIM
Market Cap: £3.63 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

2 min read